Equillium Inc
NASDAQ:EQ
Equillium Inc
Accrued Liabilities
Equillium Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Accrued Liabilities
$5.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$7.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$17.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$2.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
20%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Accrued Liabilities?
Accrued Liabilities
5.3m
USD
Based on the financial report for Sep 30, 2024, Equillium Inc's Accrued Liabilities amounts to 5.3m USD.
What is Equillium Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
27%
Over the last year, the Accrued Liabilities growth was -35%. The average annual Accrued Liabilities growth rates for Equillium Inc have been 11% over the past three years , 27% over the past five years .
You don't have any saved screeners yet